136 related articles for article (PubMed ID: 8345791)
1. Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells.
Edwards CM; Otal MP; Stacpoole PW
Metabolism; 1993 Jul; 42(7):807-13. PubMed ID: 8345791
[TBL] [Abstract][Full Text] [Related]
2. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.
Walli AK; Seidel D
J Clin Invest; 1984 Sep; 74(3):867-79. PubMed ID: 6470142
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.
Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ
Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902
[TBL] [Abstract][Full Text] [Related]
4. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.
Kostner GM; Gavish D; Leopold B; Bolzano K; Weintraub MS; Breslow JL
Circulation; 1989 Nov; 80(5):1313-9. PubMed ID: 2530005
[TBL] [Abstract][Full Text] [Related]
5. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Yu L; Qiu S; Genest J
Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
[TBL] [Abstract][Full Text] [Related]
6. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-X fifty years after its original discovery.
Fellin R; Manzato E
Nutr Metab Cardiovasc Dis; 2019 Jan; 29(1):4-8. PubMed ID: 30503707
[TBL] [Abstract][Full Text] [Related]
8. Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.
Gianturco SH; Gotto AM; Jackson RL; Patsch JR; Sybers HD; Taunton OD; Yeshurun DL; Smith LC
J Clin Invest; 1978 Feb; 61(2):320-8. PubMed ID: 202612
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
[TBL] [Abstract][Full Text] [Related]
10. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
11. Individual variation in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. Studies of low density lipoprotein receptor activity and 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in blood mononuclear cells.
Mistry P; Miller NE; Laker M; Hazzard WR; Lewis B
J Clin Invest; 1981 Feb; 67(2):493-502. PubMed ID: 6257763
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
13. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
al Rayyes O; Wallmark A; Florén CH
Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
[TBL] [Abstract][Full Text] [Related]
14. The regulation of 3-hydroxy-3-methylglutaryl-CoA reductase activity, cholesterol esterification and the expression of low-density lipoprotein receptors in cultured monocyte-derived macrophages.
Knight BL; Patel DD; Soutar AK
Biochem J; 1983 Feb; 210(2):523-32. PubMed ID: 6305342
[TBL] [Abstract][Full Text] [Related]
15. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
[TBL] [Abstract][Full Text] [Related]
16. Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.
Cohen LH; Griffioen M; Havekes L; Schouten D; van Hinsbergh V; Kempen HJ
Biochem J; 1984 Aug; 222(1):35-9. PubMed ID: 6089762
[TBL] [Abstract][Full Text] [Related]
17. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by reversible phosphorylation: modulation of enzymatic activity by low density lipoprotein, sterols, and mevalonolactone.
Beg ZH; Reznikov DC; Avigan J
Arch Biochem Biophys; 1986 Jan; 244(1):310-22. PubMed ID: 3004340
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum.
Fei H; Maeda S; Kirii H; Fujigaki S; Maekawa N; Fujii H; Wada H; Saito K; Seishima M
Clin Chem; 2000 Sep; 46(9):1351-6. PubMed ID: 10973865
[TBL] [Abstract][Full Text] [Related]
19. Role of lipoproteins and 3-hydroxy-3-methylglutaryl coenzyme A reductase in progesterone production by cultured bovine granulosa cells.
Savion N; Laherty R; Cohen D; Lui GM; Gospodarowicz D
Endocrinology; 1982 Jan; 110(1):13-22. PubMed ID: 6274615
[TBL] [Abstract][Full Text] [Related]
20. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
Liang K; Vaziri ND
Kidney Int; 2003 Jul; 64(1):192-8. PubMed ID: 12787409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
